These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38206709)

  • 1. Efficacy and safety of once-weekly basal insulin versus once-daily basal insulin in patients with type 2 diabetes: A systematic review and meta-analysis.
    Wang X; Xiao W; Liang Z; Li S; Tang Q
    Medicine (Baltimore); 2023 Dec; 102(52):e36308. PubMed ID: 38206709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials.
    Shetty S; Suvarna R
    Diabetes Obes Metab; 2024 Mar; 26(3):1069-1081. PubMed ID: 38192022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-Weekly Insulin Icodec in Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials (ONWARDS Clinical Program).
    Lisco G; De Tullio A; De Geronimo V; Giagulli VA; Guastamacchia E; Piazzolla G; Disoteo OE; Triggiani V
    Biomedicines; 2024 Aug; 12(8):. PubMed ID: 39200316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-Weekly Insulin Icodec
    Ribeiro E Silva R; de Miranda Gauza M; Guisso MES; da Silva JON; Kohara SK
    Arch Endocrinol Metab; 2023 May; 67(5):e000614. PubMed ID: 37249450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis.
    Mukhopadhyay P; Chatterjee P; Pandit K; Sanyal D; Ghosh S
    Endocr Pract; 2024 Feb; 30(2):128-134. PubMed ID: 37984730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
    Lingvay I; Asong M; Desouza C; Gourdy P; Kar S; Vianna A; Vilsbøll T; Vinther S; Mu Y
    JAMA; 2023 Jul; 330(3):228-237. PubMed ID: 37354562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of once-weekly versus once-daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis.
    Karakasis P; Patoulias D; Pamporis K; Popovic DS; Stachteas P; Bougioukas KI; Fragakis N; Rizzo M
    Diabetes Obes Metab; 2023 Dec; 25(12):3648-3661. PubMed ID: 37667676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes With Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Insulin-Naïve and Previously Insulin-Treated Individuals With Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials.
    Ahmed M; Shafiq A; Javaid H; Jain H; Nashwan AJ; Tul-Ain Q; Basit J
    Endocrinol Diabetes Metab; 2024 May; 7(3):e00480. PubMed ID: 38659132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O;
    N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
    Bajaj HS; Bergenstal RM; Christoffersen A; Davies MJ; Gowda A; Isendahl J; Lingvay I; Senior PA; Silver RJ; Trevisan R; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1586-1594. PubMed ID: 33875485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
    N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
    Lingvay I; Buse JB; Franek E; Hansen MV; Koefoed MM; Mathieu C; Pettus J; Stachlewska K; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1595-1603. PubMed ID: 33875484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
    Philis-Tsimikas A; Asong M; Franek E; Jia T; Rosenstock J; Stachlewska K; Watada H; Kellerer M
    Lancet Diabetes Endocrinol; 2023 Jun; 11(6):414-425. PubMed ID: 37148899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) : A Randomized Trial.
    Bajaj HS; Aberle J; Davies M; Donatsky AM; Frederiksen M; Yavuz DG; Gowda A; Lingvay I; Bode B
    Ann Intern Med; 2023 Nov; 176(11):1476-1485. PubMed ID: 37748181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
    Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
    Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.
    Ayesh H; Suhail S; Ayesh S; Niswender K
    Diabetes Obes Metab; 2024 Sep; 26(9):3801-3809. PubMed ID: 38923379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
    Kazda CM; Bue-Valleskey JM; Chien J; Zhang Q; Chigutsa E; Landschulz W; Wullenweber P; Haupt A; Dahl D
    Diabetes Care; 2023 May; 46(5):1052-1059. PubMed ID: 36920867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials.
    Rodbard HW; Gough S; Lane W; Korsholm L; Bretler DM; Handelsman Y
    Endocr Pract; 2014 Apr; 20(4):285-92. PubMed ID: 24246344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Once-Weekly Insulin Regimes on Glycemic Control for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Wang P; Zhang Y; Xu W; He J; Peng L; Feng Y; Xu P; Chong W; Hai Y; Jia L; Fang F
    Diabetol Metab Syndr; 2024 Jan; 16(1):3. PubMed ID: 38172995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Sep; 16(9):102615. PubMed ID: 36108418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.